Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study-Reference-Cited by-同舟云学术

Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study

Published:2020-10 Issue:4 Volume:69 Page:578-587
ISSN:1323-8930
Container-title:Allergology International
language:en
Short-container-title:Allergology International

Author:

Tohda Yuji,Nakamura Yoichi,Fujisawa Takao,Ebisawa Motohiro^ORCID,Arima Kazuhiko,Miyata Masanori,Takahashi Yoshinori,Rice Megan S.,Deniz Yamo,Rowe Paul,Patel Naimish,Graham Neil M.H.,Teper Ariel

Funder

Sanofi and Regeneron Pharmaceuticals, Inc.

Sanofi Genzyme and Regeneron Pharmaceuticals, Inc

Publisher

Elsevier BV

Subject

General Medicine,Immunology and Allergy

Reference27 articles.

1. Japanese Society of Allergology. Japanese guidelines for adult asthma 2017;Ichinose;Allergol Int,2017

2. Global Strategy for Asthma Management and Prevention;Global Initiative for Asthma (GINA),2019

3. Japanese society of pediatric allergy and clinical immunology, Japanese society of allergology. Japanese guidelines for childhood asthma 2017;Arakawa;Allergol Int,2017

4. GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study;Bateman;Am J Respir Crit Care Med,2004

5. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment;Peters;Respir Med,2006

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Immunogenicity of biologics used in the treatment of asthma;Human Antibodies;2024-07-24

3. Long-term Safety and Efficacy of Dupilumab in Patients With Uncontrolled, Moderate-to-Severe Asthma Recruited From Korean Centers: A Subgroup Analysis of the Phase 3 LIBERTY ASTHMA TRAVERSE Trial;Allergy, Asthma & Immunology Research;2024

4. Addressing therapeutic inertia for asthma biologics: Lessons from the KOFU study;Respiratory Investigation;2023-11

5. Real-world impact of dupilumab on asthma disease burden in Japan: The CROSSROAD study;Allergology International;2023-10